A
Andrea V. Margulis
Researcher at Harvard University
Publications - 58
Citations - 1614
Andrea V. Margulis is an academic researcher from Harvard University. The author has contributed to research in topics: Pregnancy & Overactive bladder. The author has an hindex of 16, co-authored 55 publications receiving 1225 citations. Previous affiliations of Andrea V. Margulis include Brigham and Women's Hospital & Food and Drug Administration.
Papers
More filters
Journal ArticleDOI
Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa Scale and the RTI item bank
Andrea V. Margulis,Manel Pladevall,Nuria Riera-Guardia,Cristina Varas-Lorenzo,Lorna Hazell,Nancy D. Berkman,Meera Viswanathan,Susana Perez-Gutthann +7 more
TL;DR: The RTI-IB facilitates a more complete quality assessment than the NOS but is more burdensome; the observed agreement and AC1 statistic in this study were higher than those reported by the RTI’s developers.
Journal ArticleDOI
Use of topiramate in pregnancy and risk of oral clefts
Andrea V. Margulis,Allen A. Mitchell,Suzanne M. Gilboa,Martha M. Werler,Murray A. Mittleman,Murray A. Mittleman,Robert J. Glynn,Sonia Hernandez-Diaz +7 more
TL;DR: First-trimester use of topiramate monotherapy in pregnancy and cleft lip with or without cleft palate in the offspring may be associated with CL/P.
Journal ArticleDOI
Algorithms to estimate the beginning of pregnancy in administrative databases.
Andrea V. Margulis,Andrea V. Margulis,Soko Setoguchi,Soko Setoguchi,Soko Setoguchi,Murray A. Mittleman,Murray A. Mittleman,Robert J. Glynn,Robert J. Glynn,Colin R. Dormuth,Sonia Hernandez-Diaz +10 more
TL;DR: Algorithms were developed and validated to estimate the gestational age at birth using information available in administrative databases for research on drug safety during pregnancy.
Posted ContentDOI
Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Jennifer C E Lane,J Weaves,Kristin Kostka,T Duarte-Salles,Abrahao,Heba Alghoul,Osaid Alser,Thamir M. Alshammari,Patricia Biedermann,Edward Burn,Paula Casajust,Mitchell M. Conover,Aedín C. Culhane,A Daydov,Scott L. DuVall,Dmitry Dymshyts,Sergio Fernandez-Bertolin,Kristina Fišter,Jill Hardin,Laura Hester,George Hripcsak,Seamus Kent,Sajan Khosla,Spyros Kolovos,Christophe G. Lambert,J van der Lei,A Londhe,Kristine E. Lynch,Rupa Makadia,Andrea V. Margulis,Michael E. Matheny,Paras P. Mehta,Daniel R. Morales,H Morgan-Stewart,M Mossveld,Danielle Newby,Fredrik Nyberg,Anna Ostropolets,Rae Woong Park,A Prats Uribe,R Gowtham,Christian G. Reich,Jenna Reps,Peter R. Rijnbeek,Sathappan Smk.,Martijn J. Schuemie,Sarah Seager,Anthony G. Sena,Azza Shoaibi,Matthew E. Spotnitz,Marc A. Suchard,Joel N. Swerdel,C Torre,David Vizcaya,Haini Wen,M. de Wilde,Seng Chan You,Lin Zhang,Oleg Zhuk,Patrick B. Ryan,D Prieto Alhambra +60 more
TL;DR: Short-term hydroxychloroquine treatment is safe, but addition of azithromycin may induce heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length.
Journal ArticleDOI
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study.
Jennifer C E Lane,James Weaver,Kristin Kostka,Talita Duarte-Salles,Maria Tereza Fernandes Abrahão,Heba Alghoul,Osaid Alser,Thamir M. Alshammari,Patricia Biedermann,Juan M. Banda,Edward Burn,Paula Casajust,Mitchell M. Conover,Aedín C. Culhane,Alexander Davydov,Scott L. DuVall,Scott L. DuVall,Dmitry Dymshyts,Sergio Fernandez-Bertolin,Kristina Fišter,Jill Hardin,Laura Hester,George Hripcsak,George Hripcsak,Benjamin Skov Kaas-Hansen,Seamus Kent,Sajan Khosla,Spyros Kolovos,Christophe G. Lambert,Johan van der Lei,Kristine E. Lynch,Kristine E. Lynch,Rupa Makadia,Andrea V. Margulis,Michael E. Matheny,Paras P. Mehta,Daniel R. Morales,H Morgan-Stewart,Mees Mosseveld,Danielle Newby,Fredrik Nyberg,Anna Ostropolets,Rae Woong Park,Albert Prats-Uribe,Gowtham A. Rao,Christian G. Reich,Jenna Reps,Peter R. Rijnbeek,Selva Muthu Kumaran Sathappan,Martijn J. Schuemie,Sarah Seager,Anthony G. Sena,Anthony G. Sena,Azza Shoaibi,Matthew E. Spotnitz,Marc A. Suchard,Carmine O. Torre,David Vizcaya,Haini Wen,Marcel de Wilde,Junqing Xie,Seng Chan You,Lin Zhang,Lin Zhang,Oleg Zhuk,Patrick B. Ryan,Patrick B. Ryan,Daniel Prieto-Alhambra +67 more
TL;DR: Hydxychloroquine treatment appears to have no increased risk in the short term among patients with rheumatoid arthritis, but in the long term it appears to be associated with excess cardiovascular mortality.